Global Stem Cells Market Size and Forecast to 2030

The scale of the global stem cell market is likely to attain the revenue of ~USD 11 billion in 2021. It is expected to grow at a compound annual growth rate (CAGR) of 10% from 2022 to 2030. Factors contributing to growth include increasing demand for biologics, technological advances in stem cell therapies, and increasing attention to the development of personalized medicines. Increasing attention to the treatment of neurological diseases helps expand the market. According to the World Health Organization (WHO), about 7.1% of the global disease burden is cerebrovascular disease and neurological disease. Therefore, the company is conducting basic research and preclinical trials to test the regenerative ability of stem cells in treating neurological diseases.

 

For example, in May 2020, Celavie Biosciences advanced a five-year exploratory study on Parkinsons disease. The company is developing regenerative stem cell therapy to treat central nervous system diseases and Parkinsons disease. Celavie Biosciences published the successful results of an exploratory clinical trial of OK99 stem cells to treat Parkinsons disease. In addition, the increasing popularity of personalized medicine has further promoted the growth of the market. Researchers are discovering new procurement methods that can be further applied to develop personalized medicines.

 

For example, iPSC therapy is developed using a small sample of blood or skin cells from a patient, and then reprogrammed to form new cells and tissues for transplantation. Therefore, through the application of these cells, potential personalized medicines can be developed. In addition, the company is focusing on developing treatments to reduce the different types of stress associated with COVID-19. For example, in October 2020, NoveCite and Novellus Therapeutics Limited collaborated to develop and commercialize NoveCite iPSC to treat COVID-19-related acute respiratory distress syndrome (ARDS). This process has a multi-modal immunomodulatory mechanism of action, making it a promising therapy for the treatment of acute respiratory diseases.

 

PRODUCT INFORMATION: The adult stem cell (ASC) segment will dominate the market in 2020 with a share of 85.7%. The main factors contributing to the advantages of market segments include the existence of minimal controversial issues regarding ethics, immune rejection, and tumor occurrence. The application of ASC in regenerative medicine can also be attributed to the growth of this market segment. It is expected that the ASC bioprocess for regenerative medicine will face challenges in the process development process. ASC is further subdivided into hematopoietic stem cells, mesenchymal stem cells (MSC), neural stem cells and epithelial/skin stem cells.

 

Due to its potential use in autologous transplantation, large-scale clinical trials marking its application in the treatment of various diseases, and extensive research exploring its potential therapeutic applications, it is expected that the MSC market segment will be the fastest composite Annual growth rate increases. Due to increased investment in the use of iPSC to develop regenerative drugs, the stem cell segment (iPSC) is expected to achieve a compound annual growth rate of 9.3% in 2021-2028, ensuring repeatability and maintenance, and being able to differentiate into all cell types and high proliferation capabilities. Due to the increasing importance of iPSC in the treatment of various diseases, the company is expanding its related services.

 

For example, in December 2020, REPROCELL launched a new personal service "iPS" service to generate patient-specific iPSCs starting in January 2021. The service will help prepare and store a persons iPSC to develop regenerative medicines for the treatment of future diseases or injuries. They are produced from mature cells by combining with out-of-the-box RNA reprogramming technology.

 

APPLICATION INFROMATION: Application areas can be divided into regenerative medicine and drug discovery and development. Due to the increase in approvals for clinical trials of stem cell therapies for different diseases, regenerative medicine will have the largest market share in 2020 at 89.1%. For example, in June 2020, Longeveron LLC announced that it has received approval from the Pharmaceutical and Medical Device Agency (PMDA) of Japan to evaluate the safety and effectiveness of its mesenchymal stem cells (LMSC) in a preliminary phase 2 clinical trial, which can be used in Treat the fragility of aging. In addition, some governments are investing heavily in the development of regenerative drugs. For example, in March 2020, the Canadian government invested approximately US$6.9 million in regenerative medicine research.

 

This funding will support 4 clinical trials and 9 translational projects, aiming to bring new therapies to the field of regenerative medicine. The regenerative drugs developed will help treat various heart diseases, blood diseases, vision loss and diabetes. The compound annual growth rate of the drug discovery and development sector is expected to reach 9.4% between 2021 and 2028. The penetration rate of market products in drug discovery is increasing because it helps to study the etiology of human diseases, determine the pathological mechanism and formulate treatment strategies to solve various problems. disease. IPSC-based models are superior to phenotypic screening because they can mimic the patients molecular and cellular phenotype. By using them, pharmaceutical companies can test hypothetical drug mechanisms in vitro in a cost-effective manner before conducting clinical trials.

 

TREATMENT INFORMATION: Allogeneic stem cell therapy accounts for 58.2% of the 2020 revenue share. Allogeneic stem cells are widely used in cancer treatment because of their transplant anti-cancer effects. With this effect, donor stem cells can use your immune system cells to destroy cancer cells. The donors immune system response is stronger than the recipients immune system. In addition, these are commonly used to treat different types of cancers, such as lymphoma, leukemia, and myeloma. During the prognosis period, autologous therapy is expected to expand to a profitable compound annual growth rate. This increase can be attributed to the advantages of fewer changes in transplant rejection and therefore fewer complications. Other factors contributing to the growth of this segment include high patient survival rates, affordability, no need to perform HLA typing for matched donors, and low risk. The application of these cells may continue to be untested in clinical trials or face stringent manufacturing standard.

 

REGIONAL INFORMATION: North America has the largest market share in 2020 at 52.1%; the growth in this region can be attributed to multiple factors, such as the presence of major players involved in the development of stem cell therapy, advanced medical infrastructure, extensive research and development, and medical support Institutional reforms and a strong refund policy. Due to government initiatives and the countrys extensive research activities, the United States is the leading country in the region. Health organizations are promoting the use of cell therapy to treat emerging diseases. For example, in April 2020, the U.S. Food and Drug Administration (FDA) approved an exploratory clinical trial efficacy study using umbilical cord-derived MSC to prevent life-threatening lung inflammation in COVID-19 patients. Due to the continuous development of stem cell therapy, government initiatives to develop regenerative drugs, the installation of multiple stem cell banks, and the increase in regenerative drug clinical trials, it will grow at the fastest compound annual growth rate of 9.0% in the forecast year. area.

 

For example, in July 2020, MEDIPOST announced the results of the NEUROSTEM phase 1/2a study. It is an investigational stem cell therapy that can be used to treat Alzheimers disease. Main company and market share information: The companys stem cell therapy is gradually being approved. For example, in April 2020, Mesoblast Ltd received an IND (Investigative New Drug Application) from the US FDA for the candidate MSC product remestemcel-L. It is used to treat patients with acute respiratory distress syndrome (ARDS) in COVID-19 .

 

SOME MAJOR PLAYERD OPERATING IN THE GLOBAL STEM CEL MARKET INCLUDE: CELGENE CORPORATION, ReNeuron Group plc , Virgin Health Bank, Biovault family , Precious Cells International Ltd , Mesoblast Ltd , Caladrius Seneca Biopharmaceuticals Inc, Opexa Therapeutics, Inc Pluristem Therapeutics Inc, STEMCELL Technologies Inc, ThermoGetellas Inc, Cell Engineering Technology BioTime Inc . MMARKET SEGMENT COVERD BY THE REPORT: The report forecasts global, regional and national revenue growth, and analyzes the latest trends and opportunities in each market segment from 2022-2030. For this report, Grand View Research has subdivided the global stem cell market. The report is divided by product, application, technology, treatment and region: Product outlook (revenue, million dollars, 2022-2030): adult stem cell (ASC) hematopoiesis, Mesenchyme, nerve, epithelium/skin, etc. Human embryonic stem cell (HESC) induced pluripotent stem cells (iPSC), Very small embryonic stem cell. Application prospects (revenue, millions of dollars, 2022-2030): Regenerative Medicine, Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Injury 2022-2030): Cell collection, bone collection, bone marrow collection, umbilical cord blood apheresis, cell production, therapeutic clones, in vitro fertilization cell culture, isolation, cryopreservation, expansion, and subculture. Therapeutic prospects (revenue, millions of dollars, 2022-2030): autologous allogeneic. "

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.